Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAPP-SVD: GLP-1 Analogue in Preventing Progression of Small Vessel Disease
NCT05356104Phase 2Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- May 2022
- Primary completion
- May 2027
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of exenatide, semaglutide in Cerebral Small Vessel Disease (CSVD), sponsored by The Chinese University of Hong Kong. Started May 2022; status: recruiting.
02
Drugs
exenatidesemaglutide
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT05356104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05356104.